MPs urge Government to review regulations for direct-to-consumer genetic testing
By Science and Technology Committee,
UK Parliament
| 06. 22. 2021
The popularity of genomics tests sold directly to consumers has increased in recent years, with products focusing on ancestry, health outcomes and genetic traits. Today, the Science and Technology Committee publishes its Direct-to-consumer genomic testing Report, urging policymakers to seize opportunities and address risks posed by the increasing availability and scope of consumer genomic testing.
Drawing on evidence taken from genomic testing companies, healthcare professionals and think tanks, the Committee's Report makes a number of recommendations for the Government to consider when updating regulations, including:
- Pre-market assessment of direct-to-consumer tests by an independent body. This assessment should cover the test's clinical performance (the extent to which it can provide information about treatment of a disease, and the likelihood of improved outcomes) in addition to the current requirement to achieve analytical performance, which describes how well the test can identify the presence of a particular gene.
- The development of technical standards for direct-to-consumer genomic testing, enabling the data generated to be used and relied upon by Genomics England and the NHS. Clearly defining such standards would facilitate research efforts...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Susanna Smith, Genetic Frontiers | 07.28.2025
Key Topics
How does the American far right view genetics and genetic technologies?
What is the history of the American cultural pursuit of trying to choose smarter children? What has science shown us about the relationship of heredity and intelligence...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick, Issues in Science and Technology | 07.04.2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to...